Comparison · NCT00981045-sae
Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): serious adverse events. Trial comparisons, record NCT00981045-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00981045-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.158 | 0.139 | 0.179 | wilson | |
| Risk in group 2 | 0.153 | 0.135 | 0.174 | wilson | |
| Risk difference, group 1 minus group 2 | 0.005 | -0.0231 | 0.0331 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.862 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.839 | 1.29 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ferric Carboxymaltose (FCM) than on Iron Sucrose (Venofer) | 200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ferric Carboxymaltose (FCM) | Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg | 202 | 1,276 | EG000 |
| Group 2 | Iron Sucrose (Venofer) | Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg | 197 | 1,285 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- September 4, 2009 through June 15, 2011
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
- NCT number
- NCT00981045
- Phases
- PHASE3
- Conditions
- Iron Deficiency Anemia, Impaired Renal Function
- Interventions
- Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer)
- Lead sponsor
- American Regent, Inc.
- Results first posted
- 2013-10-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00981045?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00981045-sae